| Welcome
to the 12th issue of PharmaView!
Pharmaceutical Marketers
are facing increasing pressures: increasing competition; squeezed
margins; shrinking budgets; more to do and less time to do it. It’s
becoming difficult to work any harder, and of course it's always
better to work smarter. Therefore we bring you the PharmaView.
PharmaView is a biweekly
educational and informative newsletter for improving readers’
marketing knowledge and reporting the latest news in the pharma
industry. It also provides great opportunities to exchange ideas,
network and be recognized among your peers in the
industry.
Through PharmaView, you can:
Learn peer’s experience
in pharma marketing
Stay in touch with what’s
happening in pharmaceutical marketing today
Be on the pioneering edge
of pharmaceutical marketing
Have networking / idea
exchange opportunities
 About
Us
Integrating local knowledge with international
perspective, Consultech Co. Ltd. offers its clients and
prospects one-lstop solutions with sales and marketing consultancy,
advertising and promotion strategies.
Consultech is an
affiliate company of Omnicom, the world's largest advertising and
communications holding company
Creative
Design: Case Study of
LifeScan's One Touch Ultra
Lipitor Receives FDA Approval for Five New Indications in Patients
With Heart Disease
Pfizer announced today that the
U.S. Food and Drug Administration (FDA) has approved Lipitor(R)
(atorvastatin calcium) Tablets to reduce the risk of nonfatal heart
attacks, fatal and non-fatal strokes, certain types of heart
surgery, hospitalization for heart failure, and chest pain in
patients with heart disease.
Mar 07, 2007
FDA Approves New Drug Treatment for High Blood Pressure
The U.S. Food and Drug
Administration (FDA) today announced the approval of Tekturna
(aliskiren) tablets for the treatment of high blood pressure, or
hypertension, which affects an estimated 25 percent of Americans and
causes increased risk of stroke, heart attack, kidney failure, heart
failure and death.
Mar 07, 2007
Humira (Adalimumab) Receives FDA Approval For Treatment of Crohn's
Disease
Abbott announced today it has
received U.S. Food and Drug Administration (FDA) approval to market
HUMIRA(R) (adalimumab) as a treatment for reducing the signs and
symptoms and inducing and maintaining clinical remission in adults
with moderately to severely active Crohn's disease who have had an
inadequate response to conventional therapy.
Feb 27, 2007
Generating high performance for pharmaceutical sales forces through
competency modeling
In competitive markets like the
pharmaceutical industry, a high performance sales force is a
strategic weapon. The right front-line sales people do far more than
just close deals. They identify market needs, provide input for the
development of new products and solutions and convey feedback from
customers to marketing, management and product developers.
Feb 27, 2007
The TV spot begins on an ominous
note. "This time last year, Jack was diagnosed with high
cholesterol." Zoom to an empty chair surrounded by family members
sharing a holiday dinner. "He thought he was fine. He wasn't."
Sure sounds depressing. But don't
worry: Jack is fine. He was just in the kitchen carving a turkey.
Mar 02,
2007
Global Market for Cancer Immunotherapy Worth $37.2 Billion by 2012
According to a new and updated
technical market research report, Immunotherapy for Cancer - PHM053A
from BCC REsearch, the global market for immunotherapies to treat
cancer was worth $19.6 billion in 2006 and will reach $23.7 billion
by the end of 2007. At a compound annual growth rate (CAGR) of 9.5%,
the global market will be worth more than $37.2 billion by 2012.
Mar 07, 2007
When is a hit a miss? What doctors
love (and hate) about the internet
Physician use of the internet
remains one of the great unknowns of medical marketing. Yes, there
are data about how many physicians own computers and use the
internet.
Mar 07, 2007
Segment-Based Marketing: From Dream to Reality
A quick market analysis of the
pharmaceutical industry reveals a proverbial "good news, bad news"
scenario. The good news: From 1995 to 2000, the industry
outperformed the S&P 500 on every major financial measure, including
net profit margin.
Mar 07, 2007
Please feel free to offer your opinions and advices about
PharmaView in order to better our services. Should you have any
comments, or if you want to unsubscribe from PharmaView,
please send us an email:
pharmaview@Consultech.com.cn . Thank
you!
| 
